<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-166
Date of Submission: 2025-04-01

This report was submitted by a Other Healthcare Professional from Mays PLC Medical Center concerning patient ANON-PX-2344. The subject is a 48-year-old female with a significant medical history including osteoarthritis, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Intravenous route at a dosage of 114mg, initiated on 2025-03-23 for Neuropathic pain with the course ongoing.

On approximately 2025-03-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Maculopapular Rash. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed must and advised glass. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-166
report_date: '2025-04-01'
patient_details:
  patient_id: ANON-PX-2344
  gender: Female
  relevant_history:
  - osteoarthritis
  - asthma
  age_at_reaction: 48
suspected_drugs:
- drug_name: Gabapentin
  dosage: 114mg
  route_of_administration: Intravenous
  start_date: '2025-03-23'
  indication_for_use: Neuropathic pain
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2025-03-27'
  severity: Mild
  outcome: Unknown
  intervention_required: true
- symptom_name: Maculopapular Rash
  onset_date: '2025-03-27'
  severity: Severe
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed must and advised glass.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 4
reporting_facility: Mays PLC Medical Center
reporter_type: Other Healthcare Professional
